Mostrar el registro sencillo del ítem

Artículo

dc.creatorSalguero-Aranda, Carmenes
dc.creatorAmaral, Ana Teresaes
dc.creatorOlmedo Pelayo, Joaquínes
dc.creatorDiaz-Martin, Juanes
dc.creatorÁlava Casado, Enrique dees
dc.date.accessioned2020-08-26T16:52:03Z
dc.date.available2020-08-26T16:52:03Z
dc.date.issued2020
dc.identifier.citationSalguero-Aranda, C., Amaral, A.T., Olmedo-Pelayo, J., Diaz-Martin, J. y Álava, E.d. (2020). Breakthrough Technologies Reshape the Ewing Sarcoma Molecular Landscape. Cells, 9 (4)
dc.identifier.issn2073-4409es
dc.identifier.urihttps://hdl.handle.net/11441/100465
dc.description.abstractEwing sarcoma is a highly aggressive round cell mesenchymal neoplasm, most often occurring in children and young adults. At the molecular level, it is characterized by the presence of recurrent chromosomal translocations. In the last years, next-generation technologies have contributed to a more accurate diagnosis and a refined classification. Moreover, the application of these novel technologies has highlighted the relevance of intertumoral and intratumoral molecular heterogeneity and secondary genetic alterations. Furthermore, they have shown evidence that genomic features can change as the tumor disseminates and are influenced by treatment as well. Similarly, next-generation technologies applied to liquid biopsies will significantly impact patient management by allowing the early detection of relapse and monitoring response to treatment. Finally, the use of these novel technologies has provided data of great value in order to discover new druggable pathways. Thus, this review provides concise updates on the latest progress of these breakthrough technologies, underscoring their importance in the generation of key knowledge, prognosis, and potential treatment of Ewing Sarcomaes
dc.description.sponsorshipJunta de Andalucía, Consejería de Salud PI-0036-2017 y PI-0040-2017es
dc.description.sponsorshipFundación María García Estradaes
dc.description.sponsorshipUniversidad de Sevillaes
dc.description.sponsorshipJuan de la Cierva Incorporación IJC-2018-036767-Ies
dc.description.sponsorshipLaboratorio de EdA compatible por el proyecto AECC GCB13-1578, ISCIIIFEDER PI14 / 01466, PI17 / 00464, CIBERONC CB16 / 12/00361es
dc.description.sponsorshipFundación CRIS Contra el Cánceres
dc.formatapplication/pdfes
dc.format.extent16es
dc.language.isoenges
dc.publisherMDPIes
dc.relation.ispartofCells, 9 (4)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectSarcomaes
dc.subjectEwing sarcomaes
dc.subjectGFes
dc.subjectExtracellular vesicleses
dc.subjectCirculating tumor DNA/RNAes
dc.subjectDNA repaires
dc.subjectBreakthrough technologieses
dc.subjectMutationses
dc.titleBreakthrough Technologies Reshape the Ewing Sarcoma Molecular Landscapees
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Citología e Histología Normal y Patológicaes
dc.relation.publisherversionhttps://doi.org/10.3390/cells9040804es
dc.identifier.doi10.3390/cells9040804es
dc.journaltitleCellses
dc.publication.volumen9es
dc.publication.issue4es

FicherosTamañoFormatoVerDescripción
cells-09-00804-v2.pdf1.610MbIcon   [PDF] Ver/Abrir   Breakthrough Technologies

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional